A CLINICAL TRIAL OF NALIDIXIC ACID: A NEW ANTIBACTERIAL SUBSTANCE.
D000421:Alcaligenes; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004351:Drug Resistance; D004352:Drug Resistance, Microbial; D004358:Drug Therapy; D004754:Enterobacter; D004927:Escherichia coli Infections; D009268:Nalidixic Acid; D009287:Naphthyridines; D011512:Proteus Infections; D011552:Pseudomonas Infections; D013203:Staphylococcal Infections; D013290:Streptococcal Infections; D014116:Toxicology; D014552:Urinary Tract Infections
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D009287:Naphthyridines; D009268:Nalidixic Acid
AEROBACTER; ALCALIGENES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY; ESCHERICHIA COLI INFECTIONS; NAPHTHYRIDINES; PROTEUS INFECTIONS; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; TOXICOLOGIC REPORT; URINARY TRACT INFECTIONS